Amandeep Godara
( out of 1024 reviews )

Amandeep Godara, MBBS

Languages spoken: English, Hindi

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-587-7000
Get Directions

Dr. Amandeep Godara is an Associate Professor with the Division of Hematology & Hematologic Malignancies. He completed his Hematology-Oncology fellowship at Tufts Medical Center with a clinical and research interest in plasma cell disorders. His research focuses on developing new therapeutic targets and tools for assessment of treatment response in Multiple Myeloma, Amyloidosis and other monoclonal gammopathies. His work has been presented at national and international scientific meetings. He was a recipient of the Amyloidosis Foundation David Seldin, MD, PhD Memorial Research Grant. He also received training in blood and marrow transplantation at Stanford University. He completed his medical school at Government Medical College, Aurangabad, India and his internal medicine residency at Wayne State University. Dr. Godara treats patients with Multiple Myeloma, Amyloidosis, Waldenström's Macroglobulinemia, and other plasma cell disorders.

Specialties

Board Certification

American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

Patients consistently describe Dr. Godara as knowledgeable, professional, and clear in explaining diagnoses and treatment options. Reviewers praise his strong communication and responsiveness, noting that he listens, answers questions, and is available when needed. Many comments highlight his compassionate bedside manner, thoroughness, and coordination of care, with patients expressing confidence and trust in his clinical judgment.

Generated via Patient Reviews

4.9 /5
( out of 1024 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Dr. Amandeep Godara is an Associate Professor with the Division of Hematology & Hematologic Malignancies. He completed his Hematology-Oncology fellowship at Tufts Medical Center with a clinical and research interest in plasma cell disorders. His research focuses on developing new therapeutic targets and tools for assessment of treatment response in Multiple Myeloma, Amyloidosis and other monoclonal gammopathies. His work has been presented at national and international scientific meetings. He was a recipient of the Amyloidosis Foundation David Seldin, MD, PhD Memorial Research Grant. He also received training in blood and marrow transplantation at Stanford University. He completed his medical school at Government Medical College, Aurangabad, India and his internal medicine residency at Wayne State University. Dr. Godara treats patients with Multiple Myeloma, Amyloidosis, Waldenström's Macroglobulinemia, and other plasma cell disorders.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor (Clinical)
Academic Divisions Hematology & Hematologic Malignancies
Board Certification
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)

Education history

Fellowship Hematology-Oncology - Tufts Medical Center Fellow
Fellowship Bone Marrow Transplantation and Immunotherapy - Stanford University School of Medicine Fellow
Residency Internal Medicine - Wayne State University School of Medicine Resident
Internship Internal Medicine - Wayne State University School of Medicine Intern
Professional Medical Medicine - Government Medical College M.B.B.S.

Selected Publications

Journal Article

  1. Mohyuddin GR, Vaquera-Alfaro HA, Godara A, Goodman A, Mainou M, Chakraborty R, Kugler HD, Meirson T (2026). Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review. EClinicalMedicine, 97, 104064.
  2. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Costello C, DAngelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson TJ, Rosenberg A, Sarosiek SR, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Ye JC, Kovach E, Kumar R (2026). Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw, 24(1).
  3. Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin GR (2025). The Past, Present and Future of Myeloma Staging and Risk Prognostication. Oncologist, 30(10).
  4. Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, DSouza A, Szabo A, Mohyuddin GR (2025). Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. Leukemia, 39(9), 2289-2291.
  5. Galarza Fortuna GM, Peres LC, Nazarenko E, De Menezes Silva Corraes A, Hovanky V, Shune L, McGuirk JP, de Avila G, Khouri J, Dima D, Gaballa MR, Dhakal B, Forsberg PA, Godara A, Afrough A, Anderson LD Jr, Herr MM, Davis JA, Mann H, Purvey S, Clark WB, Htut MM, Beitinjaneh AM, Pereira DL, Kocoglu M, Ferreri CJ, Atrash S, Voorhees PM, Rossi AC, Richard S, Hashmi H, Patel KK, Sidana S, Lin Y, Hansen DK, Sborov DW (2025). Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia. Blood Adv, 9(23), 6009-6018.
  6. Goldstein J, Stinson L, Sideris K, Waldron J, Mooney R, Barrell K, Godara A, Carter S (2025). Hereditary transthyretin amyloidosis caused by a rare mutation. BMJ Case Rep, 18(7).
  7. Mohyuddin GR, Chakraborty R, Berger K, Winborg R, Barnes MS, Hurtado Martinez JA, Hydren JR, Sborov D, Godara A, McClune B, Booth CM, Cliff ERS (2025). Patient Preferences on Clinical Decision Making in Multiple Myeloma. JCO Oncol Pract, OP2500322.
  8. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Costello C, DAngelo C, Derman B, Devarakonda S, Elsedawy N, Godara A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Vogl D, Kovach E, Kumar R (2025). NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw, 23(5), 132-140.
  9. Tan CJ, Kacerek D, Kampirapawong N, Godara A, Chaiyakunapruk N (2024). Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review. Cancer Med, 14(5), e70585.
  10. Syeed S, Tan CJ, Godara A, Gooden K, Tang D, Slaff S, Shih YH, Ngorsuraches S, Chaiyakunapruk N (2024). Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment. Pharmacoeconomics.
  11. Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz KD (2024). Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study. Healthcare (Basel), 12(16).
  12. Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz KD (2024). Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities. Healthcare (Basel), 12(16).
  13. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 64(7), 1-4.
  14. Siddiqui NS, Klein A, Godara A, Buchsbaum RJ, Hughes MC (2022). Predicting In-Hospital Mortality After Acute Myeloid Leukemia Therapy: Through Supervised Machine Learning Algorithms. JCO Clin Cancer Inform, 6, e2200044.
  15. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565.
  16. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48.
  17. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719.
  18. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int, 13, 12.
  19. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, DAngelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K (2021). HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv, 5(14), 2852-2862.
  20. Godara A, Riesenburger RI, Zhang DX, Varga C, Fogaren T, Siddiqui NS, Yu A, Wang A, Mastroianni M, Dowd R, Nail TJ, McPhail ED, Kurtin PJ, Theis JD, Toskic D, Arkun K, Pilichowska M, Kryzanski J, Patel AR, Comenzo R (2021). Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid, 28, 1-8.
  21. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, DAngelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942.
  22. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R (2021). Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. Clin Neurol Neurosurg, 206, 106708.
  23. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. J Clin Transl Sci, 5(1), e146.
  24. Godara A, Siddiqui NS, Munigala S, Dhawan R, Kansagra AJ, Rapoport AP, Yared JA, Dahiya S (2020). Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation. JCO Oncol Pract, 17(3), e355-e368.
  25. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R (2020). Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. J Clin Neurosci, 84, 33-37.
  26. Godara A, Palladini G (2020). Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis. Hematol Oncol Clin North Am, 34(6), 1145-1159.
  27. Saif MW, Hachem H, Purvey S, Hamal R, Zhang L, Siddiqui NS, Godara A, Diasio RB (2020). Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice. Arch Pharmacol Ther, 2(1), 6-8.

Review

  1. DAngelo CR, Derman BA, Devarakonda S, Godara A, Lee HC, Robinson T, Kumar S, Callander N (2026). Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement. [Review]. J Natl Compr Canc Netw, 24(5).
  2. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24(1), 15-22.

Case Report

  1. Nandakumar V, Godara A, Mensah F (2026). Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case Report. Clin Lymphoma Myeloma Leuk.
  2. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int, 13, 12.
  3. Godara A, Migliozzi DR, Pilichowska M, Goyal N, Varga C, Gordon CE (2020). Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report. Kidney Med, 2(5), 652-656.

Letter

  1. Lemieux M, Chunara F, Szabo A, Van Oekelen O, Chakraborty R, Godara A, Shaikh H, Strouse C, Mohan M, Mohyuddin GR (2026). The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis. [Letter to the editor]. Am J Hematol.
  2. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. [Letter to the editor]. Leuk Lymphoma, 65(9), 1362-1365.
  3. Zhang Y, Godara A, Pan S, Toskic D, Mann H, Sborov D, Comenzo R, Kansagra A (2022). Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. [Letter to the editor]. Ann Hematol, 101(9), 2119-2121.
  4. Godara A, Toskic D, Albanese J, Rosenthal B, Siddiqui NS, Kugelmass A, Zhou P, Fogaren T, Varga C, Landau HJ, Comenzo RL (2020). Involved free light chains 10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis. [Letter to the editor]. Am J Hematol, 96(1), E20-E23.

Other

  1. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. medRxiv. United States.

News & Podcasts

Huntsman Cancer Institute News

Podcasts